<DOC>
	<DOCNO>NCT00070590</DOCNO>
	<brief_summary>Clinical experimental study suggest bosentan could delay progression interstitial lung disease ( ILD ) associate systemic sclerosis ( SSc ) , condition establish efficacious treatment available . The present trial investigates possible use oral bosentan , currently approve treatment symptom pulmonary arterial hypertension ( PAH ) WHO Class III IV , new category patient suffer ILD associated SSc .</brief_summary>
	<brief_title>Efficacy Safety Oral Bosentan Pulmonary Fibrosis Associated With Scleroderma</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Scleroderma , Localized</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Main inclusion criterion : Systemic Sclerosis diffuse limit Significant Interstitial Lung Disease HRCTscan DLco &lt; 80 % predict Dyspnea exertion Walk limit musculoskeletal reason Main exclusion criterion : Interstitial Lung Disease due condition SSc End stage restrictive obstructive lung disease Severe cardiac renal disease Significant pulmonary arterial hypertension Smoker ( &gt; 5cig./day ) Treatment immunosuppressive , antifibrotic drug , high dose corticosteroid ( within 4 week randomization )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Scleroderma</keyword>
	<keyword>Fibrosing alveolitis</keyword>
	<keyword>Build</keyword>
	<keyword>bosentan</keyword>
</DOC>